Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

741P - Comparison of the Idylla microsatellite instability (MSI) test with a gold standard MSI test and mismatch repair immunohistochemistry in endometrial cancer

Date

14 Sep 2024

Session

Poster session 01

Topics

Pathology/Molecular Biology;  Translational Research

Tumour Site

Endometrial Cancer

Presenters

Ramona Erber

Citation

Annals of Oncology (2024) 35 (suppl_2): S544-S595. 10.1016/annonc/annonc1592

Authors

R. Erber1, I. Unser1, J. Emons2, P. Gass2, M. Ruebner2, M.W. Beckmann2, P.A. Fasching2, A. Hartmann1, R. Stöhr1

Author affiliations

  • 1 Institute Of Pathology, Friedrich-alexander-universität Erlangen-nürnberg (fau), Comprehensive Cancer Center Erlangen-emn, Comprehensive Cancer Center Alliance Wera (ccc Wera) And Bavarian Cancer Research Center (bzkf), University Hospital Erlangen, 91054 - Erlangen/DE
  • 2 Department Of Gynecology And Obstetrics, Friedrich-alexander-universität Erlangen-nürnberg (fau), Comprehensive Cancer Center Erlangen-emn, Comprehensive Cancer Center Alliance Wera (ccc Wera) And Bavarian Cancer Research Center (bzkf), University Hospital Erlangen, 91054 - Erlangen/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 741P

Background

Determination of the molecular subtype of endometrial cancer has been shown to be prognostic and predictive and is therefore essential for treatment decisions and prognosis prediction in endometrial cancer. Therefore, assessment of mismatch repair protein (MMR) deficiency by immunohistochemistry (IHC) and sequential microsatellite instability (MSI) in cases with indeterminate protein expression status is part of routine diagnostics in the diagnosis of endometrial cancer. Several methods are available for MSI analysis.

Methods

We compared the Idylla™ MSI Assay (Biocartis) with our institutional MSI gold standard test (Bethesda panel) and with MMR IHC in a cohort of n=332 hysterectomy specimen of endometrioid adenocarcinomas of the corpus uteri (2008-2016). MSI tests were performed according to the manufacturer's recommendations (Idylla™) and a validated internal protocol (Bethesda panel). MMR IHC was analyzed using tissue microarrays, but repeated on whole slides in case of a negative internal control or a discrepancy with the MSI test. The Idylla™ MSI results were compared with the Bethesda MSI results and the MMR-IHC.

Results

In our cohort of n=332 endometrioid endometrial cancer cases, MMR IHC, Idylla™ MSI and gold standard (Bethesda) MSI test results were evaluable in all cases, n=325, and n=324, respectively. N=87/332 (26.2%) had MMR deficiency (MMRd) with n=78/332 (23.5%) showing MLH1/PMS2 loss. The Idylla™ MSI assay revealed MSI in n=68/325 (20.9%) cases. Idylla™ results agreed with MMR IHC results in n=303/325 cases (overall percentage agreement (OPA)=93.2%; Kappa= 0.814). Bethesda results were consistent with MMR IHC results in n=310/324 cases (OPA=95.7%; Kappa= 0.884). Both Idylla™ and Bethesda MSI results were available for n=322/332 cases (97.0%) with n=308/322 concordant cases. OPA between the two MSI test methods was therefore 95.65% (Kappa= 0.874).

Conclusions

Idylla™ MSI showed a very high OPA with the gold standard MSI test and with MMR IHC. In view of its short turnaround time and ease of use, this test could therefore be an excellent alternative for MSI testing in endometrial cancer, even with old tissue samples.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Biocartis provided the cartridges free of charge.

Disclosure

R. Erber: Financial Interests, Institutional, Research Funding: Biocartis; Financial Interests, Personal, Invited Speaker: AstraZeneca. I. Unser, A. Hartmann, R. Stöhr: Financial Interests, Institutional, Research Funding: Biocartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.